LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC on Tuesday said it has secured regulatory approval in the US to start a phase 1/2 clinical trial for its human Retinal Progenitor Cell therapy candidate for retinitis pigmentosa.
The US Food and Drug Administration has given approval for the trial, which will investigate the use of ReNeuron's product in treating retinitis pigmentosa, a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.
The trial will be conducted at the Massachusetts Eye and Ear centre in Boston, Massachusetts.
"We are delighted to have received regulatory approval to commence our first clinical trial in the US with our hRPC stem cell therapy candidate for RP. It is a testament both to our staff and to the quality of our hRPC technology that this first-in-man clinical trial application was approved so promptly," said ReNeuron Chief Executive Olav Hellebø.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)